Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Pipeline Review, H2 2016

  • ID: 3927193
  • Report
  • 221 pages
  • Global Markets Direct
1 of 6

FEATURED COMPANIES

  • Aduro BioTech, Inc.
  • BIOCAD
  • Immunovo BV
  • MD Biosciences GmbH
  • Molecular Partners AG
  • Sutro Biopharma, Inc.
  • MORE
Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Pipeline Review, H2 2016

Summary

‘Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Pipeline Review, H2 2016’, provides in depth analysis on Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) targeted pipeline therapeutics.

The report provides comprehensive information on the Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) targeted therapeutics development and features dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1)
- The report reviews Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • Aduro BioTech, Inc.
  • BIOCAD
  • Immunovo BV
  • MD Biosciences GmbH
  • Molecular Partners AG
  • Sutro Biopharma, Inc.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) Overview

Therapeutics Development

Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Products under Development by Stage of Development

Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Products under Development by Therapy Area

Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Products under Development by Indication

Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Pipeline Products Glance

Late Stage Products

Early Stage Products

Unknown Stage Products

Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Products under Development by Companies

Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Products under Development by Universities/Institutes

Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Companies Involved in Therapeutics Development

Aduro BioTech, Inc.

Agenus, Inc.

Aurigene Discovery Technologies Limited

BeiGene, Ltd.

Beijing Hanmi Pharmaceutical Co., Ltd.

BIOCAD

Cellular Biomedicine Group, Inc.

CytomX Therapeutics, Inc.

Eli Lilly and Company

Enumeral Biomedical Holdings, Inc.

Immunovo BV

Jiangsu Hengrui Medicine Co., Ltd.

Jounce Therapeutics, Inc.

Les Laboratoires Servier SAS

MacroGenics, Inc.

MD Biosciences GmbH

MedImmune, LLC

Merck & Co., Inc.

Molecular Partners AG

Novartis AG

Ono Pharmaceutical Co., Ltd.

Pfizer Inc.

PharmaEssentia Corporation

Pieris Pharmaceuticals Inc

Regeneron Pharmaceuticals Inc

Sutro Biopharma, Inc.

Symphogen A/S

Tasly Pharmaceutical Group Co., Ltd.

Tesaro, Inc.

Theravectys SA

Tikcro Technologies, Ltd.

Vyriad

Xencor, Inc.

Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Drug Profiles

AM-0001 - Drug Profile

AMP-224 - Drug Profile

Anti-PD1 Monoclonal Antibody + Cellular Immunotherapy for Glioblastoma - Drug Profile

AUR-012 - Drug Profile

BGB-108 - Drug Profile

BGBA-317 - Drug Profile

Biologic to Antagonize CTLA4 and PD-1 for Solid Tumor - Drug Profile

Drug to Inhibit PD-1, Gal-9 and TIM-3 for Solid Tumor - Drug Profile

durvalumab + MEDI-0680 - Drug Profile

ENUM-003 - Drug Profile

ENUM-388D4 - Drug Profile

GXP-2 - Drug Profile

IBI-308 - Drug Profile

JS-001 - Drug Profile

MD-402 - Drug Profile

mDX-400 - Drug Profile

MEDI-0680 - Drug Profile

MGD-013 - Drug Profile

Monoclonal Antibodies to Antagonize PD-1 for Oncology - Drug Profile

Monoclonal Antibodies to Antagonize PD-1 for Oncology - Drug Profile

Monoclonal Antibodies to Antagonize PD1 for Metastatic Melanoma and Metastatic Lung Cancer - Drug Profile

Monoclonal Antibodies to Inhibit CTLA4 and PD-1 for Oncology - Drug Profile

Monoclonal Antibodies to Inhibit PD-1/PD-L1 for Hematological Malignancies and Bacterial Infections - Drug Profile

Monoclonal Antibody to Antagonize PD-1 for Autoimmune Disorders and Oncology - Drug Profile

Monoclonal Antibody to Antagonize PD-1 for Non-Small Cell Lung Cancer - Drug Profile

Monoclonal Antibody to Antagonize PD-1 for Oncology - Drug Profile

Monoclonal Antibody to Antagonize PD-1 for Oncology - Drug Profile

Monoclonal Antibody to Antagonize PD-1 for Oncology - Drug Profile

Monoclonal Antibody to Antagonize PD1 for Oncology - Drug Profile

Monoclonal Antibody to Antagonize PD1 for Oncology - Drug Profile

Monoclonal Antibody to Inhibit PD-1 and LAG3 for Oncology - Drug Profile

Monoclonal Antibody to Inhibit PD-1 and TIM3 for Oncology - Drug Profile

Monoclonal Antibody to Inhibit PD-1 for Cancer - Drug Profile

Monoclonal Antibody to Inhibit PD-1 for HIV - Drug Profile

Monoclonal Antibody to Inhibit PD-1 for Oncology - Drug Profile

Monocloncal Antibody to Inhibit PD-1 for Oncology - Drug Profile

nivolumab - Drug Profile

Oncolytic Virus to Activate IFNb for Head and Neck Cancer and Lewis Lung Cancer - Drug Profile

pazopanib hydrochloride + pembrolizumab - Drug Profile

PD-1 Antagonist + ropeginterferon alfa-2b - Drug Profile

PDR-001 - Drug Profile

PEGMP-7 - Drug Profile

pembrolizumab - Drug Profile

PF-06801591 - Drug Profile

PRS-332 - Drug Profile

Recombinant Protein to Inhibit VEGF-A and PD1 for Solid Tumor and Hematological Malignancies - Drug Profile

REGN-2810 - Drug Profile

SHR-1210 - Drug Profile

SNPD-07 - Drug Profile

STIA-1110 - Drug Profile

TSR-042 - Drug Profile

Vaccine to Target CD274 and CD279 for Bladder Cancer - Drug Profile

Vaccine to Target CD274 and CD279 for Colorectal Cancer - Drug Profile

Vaccine to Target CD274 and CD279 for Renal Cell Carcinoma - Drug Profile

XmAb-20717 - Drug Profile

Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Dormant Projects

Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Discontinued Products

Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Number of Products under Development for, H2 2016

Number of Products under Development by Therapy Area, H2 2016

Number of Products under Development by Indication, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Comparative Analysis by Unknown Stage Development, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Development by Companies, H2 2016 (Contd..1)

Products under Development by Companies, H2 2016

Products under Development by Companies, H2 2016 (Contd..1)

Products under Development by Companies, H2 2016 (Contd..2)

Products under Development by Companies, H2 2016 (Contd..3)

Products under Development by Companies, H2 2016 (Contd..4)

Products under Development by Companies, H2 2016 (Contd..5)

Products under Development by Companies, H2 2016 (Contd..6)

Products under Development by Companies, H2 2016 (Contd..7)

Products under Development by Companies, H2 2016 (Contd..8)

Products under Development by Companies, H2 2016 (Contd..9)

Products under Development by Companies, H2 2016 (Contd..10)

Products under Development by Companies, H2 2016 (Contd..11)

Products under Development by Companies, H2 2016 (Contd..12)

Products under Development by Companies, H2 2016 (Contd..13)

Number of Products under Investigation by Universities/Institutes, H2 2016

Products under Investigation by Universities/Institutes, H2 2016

Assessment by Monotherapy/Combination Products, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Pipeline by Aduro BioTech, Inc., H2 2016

Pipeline by Agenus, Inc., H2 2016

Pipeline by Aurigene Discovery Technologies Limited, H2 2016

Pipeline by BeiGene, Ltd., H2 2016

Pipeline by Beijing Hanmi Pharmaceutical Co., Ltd., H2 2016

Pipeline by BIOCAD, H2 2016

Pipeline by Cellular Biomedicine Group, Inc., H2 2016

Pipeline by CytomX Therapeutics, Inc., H2 2016

Pipeline by Eli Lilly and Company, H2 2016

Pipeline by Enumeral Biomedical Holdings, Inc., H2 2016

Pipeline by Immunovo BV, H2 2016

Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2016

Pipeline by Jounce Therapeutics, Inc., H2 2016

Pipeline by Les Laboratoires Servier SAS, H2 2016

Pipeline by MacroGenics, Inc., H2 2016

Pipeline by MD Biosciences GmbH, H2 2016

Pipeline by MedImmune, LLC, H2 2016

Pipeline by Merck & Co., Inc., H2 2016

Pipeline by Molecular Partners AG, H2 2016

Pipeline by Novartis AG, H2 2016

Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016

Pipeline by Pfizer Inc., H2 2016

Pipeline by PharmaEssentia Corporation, H2 2016

Pipeline by Pieris Pharmaceuticals Inc, H2 2016

Pipeline by Regeneron Pharmaceuticals Inc, H2 2016

Pipeline by Sutro Biopharma, Inc., H2 2016

Pipeline by Symphogen A/S, H2 2016

Pipeline by Tasly Pharmaceutical Group Co., Ltd., H2 2016

Pipeline by Tesaro, Inc., H2 2016

Pipeline by Theravectys SA, H2 2016

Pipeline by Tikcro Technologies, Ltd., H2 2016

Pipeline by Vyriad, H2 2016

Pipeline by Xencor, Inc., H2 2016

Dormant Projects, H2 2016

Discontinued Products, H2 2016 203List of Figures

Number of Products under Development for, H2 2016

Number of Products under Development by Therapy Area, H2 2016

Number of Products under Development by Indication, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy/Combination Products, H2 2016

Number of Products by Mechanism of Actions, H2 2016

Number of Products by Stage and Mechanism of Actions, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Type, H2 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • Aduro BioTech, Inc.
  • BIOCAD
  • Immunovo BV
  • MD Biosciences GmbH
  • Molecular Partners AG
  • Sutro Biopharma, Inc.
  • MORE
Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) pipeline Target constitutes close to 55 molecules. Out of which approximately 52 molecules are developed by Companies and remaining by the Universities/Institutes. Our latest report Programmed Cell Death Protein 1 – Pipeline Review, H2 2016, outlays comprehensive information on the Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) Programmed cell death protein 1 also known as PD-1 and CD279 is a protein that encoded by the PDCD1 gene. PD-1 is a cell surface receptor that belongs to the immunoglobulin superfamily and is expressed on T cells and pro-B cells. PD-1 functioning as an immune checkpoint plays an important role in down regulating the immune system by preventing the activation of T-cells, which in turn reduces autoimmunity and promotes self-tolerance. The inhibitory effect of PD-1 is accomplished through a dual mechanism of promoting apoptosis (programmed cell death) in antigen specific T-cells in lymph nodes while simultaneously reducing apoptosis in regulatory T cells (suppressor T cells). The molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 4, 7, 1, 25, 11 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.

Furthermore, this report also reviews key players involved in Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Driven by data built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Product cover images may vary from those shown
5 of 6
Aduro BioTech, Inc.
Agenus, Inc.
Aurigene Discovery Technologies Limited
BeiGene, Ltd.
Beijing Hanmi Pharmaceutical Co., Ltd.
BIOCAD
Cellular Biomedicine Group, Inc.
CytomX Therapeutics, Inc.
Eli Lilly and Company
Enumeral Biomedical Holdings, Inc.
Immunovo BV
Jiangsu Hengrui Medicine Co., Ltd.
Jounce Therapeutics, Inc.
Les Laboratoires Servier SAS
MacroGenics, Inc.
MD Biosciences GmbH
MedImmune, LLC
Merck & Co., Inc.
Molecular Partners AG
Novartis AG
Ono Pharmaceutical Co., Ltd.
Pfizer Inc.
PharmaEssentia Corporation
Pieris Pharmaceuticals Inc
Regeneron Pharmaceuticals Inc
Sutro Biopharma, Inc.
Symphogen A/S
Tasly Pharmaceutical Group Co., Ltd.
Tesaro, Inc.
Theravectys SA
Tikcro Technologies, Ltd.
Vyriad
Xencor, Inc.
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll